Table 2 Comparison of the incidence of major drug-related grade 3 or 4 AEs between groups at final follow-up
AEs, n (%) | CET (n=100) | BEV (n=104) | P-value |
|---|---|---|---|
Skin | 21 (21.0) | 5 (4.8) | 0.001* |
Diarrhoea | 13 (13.0) | 4 (5.4) | 0.018* |
Anorexia | 5 (5.0) | 1 (1.0) | 0.088 |
Vomiting | 7 (7.0) | 1 (1.0) | 0.026* |
Stomatitis | 5 (5.0) | 3 (2.9) | 0.436 |
Fatigue | 9 (9.0) | 2 (1.9) | 0.025* |
Thrombocytopenia | 13 (13.0) | 4 (3.8) | 0.018* |
Dysphonia | 3 (3.0) | 4 (3.8) | 0.740 |
Proteinuria | 10 (10.0) | 3 (2.9) | 0.038* |
Nausea | 8 (8.0) | 2 (1.9) | 0.044* |
Hypoalbuminemia | 8 (8.0) | 7 (6.7) | 0.728 |
Peripheral oedema | 7 (7.0) | 8 (7.7) | 0.850 |
Hepatic encephalopathy | 3 (3.0) | 5 (4.8) | 0.506 |
≥ 2 AEs in one patient | 23 (22.0) | 12 (11.5) | 0.030* |